Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
23.37(c) 23.13(c) 23.04(c) 23.18(c) 22.98 Last
618 286 609 331 894 590 1 293 172 425 461 Volume
+1.39% -1.03% -0.39% +0.61% -0.86% Change
More quotes
Financials
Sales 2020 478 M 564 M 564 M
Net income 2020 30,0 M 35,3 M 35,3 M
Net Debt 2020 145 M 171 M 171 M
P/E ratio 2020 118x
Yield 2020 -
Sales 2021 547 M 645 M 645 M
Net income 2021 48,5 M 57,2 M 57,2 M
Net Debt 2021 88,3 M 104 M 104 M
P/E ratio 2021 72,6x
Yield 2021 -
Capitalization 3 781 M 4 473 M 4 460 M
EV / Sales 2020 8,21x
EV / Sales 2021 7,07x
Nbr of Employees 3 278
Free-Float 90,7%
More Financials
Company
Evotec SE specializes in research and development services for the pharmaceutical and biotechnological industries. The group's activity is organized around 3 areas: - development of broadband screening systems; - research and development of pharmaceutical products: for the neurologic, oncologic, inflammatory diseases treatment; - other: target identification, pharmacological tests development, broadband screening... 
More about the company
Notations Surperformance© of Evotec SE
Trading Rating : Investor Rating :
More Ratings
All news about EVOTEC SE
10/20EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
10/19EVOTEC : Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing and ..
PU
10/19EVOTEC : Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing
PU
10/19EVOTEC : Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Fin..
PU
10/19EVOTEC : Baader Bank keeps its Buy rating
MD
10/19EVOTEC : secures grant to evaluate antibody drugs for COVID-19
RE
10/19EVOTEC : Just - evotec biologics receives grant to enable an antibody product fo..
EQ
10/13EVOTEC : Buy rating from RBC
MD
10/13EVOTEC : Baader Bank gives a Buy rating
MD
10/12EVOTEC : Mubadala investment company and novo holdings a/s invest € 250 m in evo..
PU
10/12EVOTEC : Mubadala Investment Company and Novo Holdings A/S invest € 250 million ..
PU
10/12EVOTEC : Mubadala investment company and novo holdings a/s invest ? 250 m in evo..
EQ
10/12EVOTEC : Mubadala Investment Company and Novo Holdings A/S invest ? 250 million ..
EQ
10/12EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
10/09EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
More news
News in other languages on EVOTEC SE
10/21BAYER IM FOKUS : Warten auf das Licht am Ende des Tunnels
10/19Aktien Frankfurt Schluss: Dax im Minus
10/19DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 19.10.2020 - 15.15 Uhr
10/19Aktien Frankfurt: Dax gerät im Verlauf unter Druck
10/19EVOTEC : Topas Therapeutics erhält 22 Mio. € (26 Mio. US$) aus Serie-B-Finanzier..
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Stock Trading Strategies
EVOTEC SE - 07/24
Back on price levels to sell
SELL
More Stock Trading Analysis
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 30,33 €
Last Close Price 23,18 €
Spread / Highest target 55,3%
Spread / Average Target 30,9%
Spread / Lowest Target 20,8%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE0.56%4 461
LONZA GROUP AG62.00%47 011
SEAGEN INC.73.04%34 401
IQVIA HOLDINGS INC.9.54%32 445
CELLTRION, INC.31.22%28 807
MODERNA, INC.249.54%26 978